Altuvoct is a medicine used to prevent and treat bleeding in adults and children with haemophilia A. Haemophilia A is an inherited bleeding disorder caused by a lack of factor VIII, a protein that helps the blood clot. Haemophilia A is rare, and Altuvoct was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 28 June 2019\. Altuvoct contains the active substance efanesoctocog alfa.
Therapeutic Indication
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Altuvoct can be used for all age groups.
Therapeutic Area (MeSH)
ATC Code
B02BD02
ATC Item
N/A
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Efanesoctocog alfa | N/A | Efanesoctocog alfa |
EMA Name
Altuvoct
Medicine Name
Altuvoct
Aliases
N/ANo risk management plan link.
